Figure 4

Oral administration of STA-5326 during the effector phase reduces the severity of experimental autoimmune uveoretinitis (EAU) by clinical analysis. Clinical score of EAU in STA-5326-treated or vehicle-treated mice. Immunized mice were treated with 20 mg/kg STA-5326 or vehicle from day 9 to day 14 after immunization. Clinical findings were evaluated on day 15 and day 18 after immunization. Statistical analysis was performed by Mann-Whitney U test.